Ipratropium bromide monohydrate, Xylometazoline HCl
Indications
Ipratropium bromide monohydrate, Xylometazoline HCl is used for:
IPRATROPIUM BROMIDE
For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
XYLOMETAZOLINE
It is used for treating nasal congestion and minor inflammation due to allergies or colds.
For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
XYLOMETAZOLINE
It is used for treating nasal congestion and minor inflammation due to allergies or colds.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ipratropium bromide monohydrate, Xylometazoline HCl :
Mechanism of Action
IPRATROPIUM BROMIDE
Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cgmp). Most likely due to actions of cgmp on intracellular calcium, this results in decreased contractility of smooth muscle.
XYLOMETAZOLINE
Xylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion.
Ipratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cgmp). Most likely due to actions of cgmp on intracellular calcium, this results in decreased contractility of smooth muscle.
XYLOMETAZOLINE
Xylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion.